Newsfile·2025-03-03 23:28Core Viewpoint - Zentek Ltd. has announced an at-the-market offering agreement to raise up to US$30 million through the sale of common shares in the United States [1][4]. Group 1: Offering Details - The offering will be conducted through an "at-the-market offering" as defined under U.S. Securities Act, with sales made directly on Nasdaq or other recognized marketplaces [3]. - The offering will remain effective until the total gross sales reach US$30 million, unless terminated earlier by any party involved [4]. - Sales will occur at prevailing market prices, which may vary, and net proceeds will be used for corporate purposes as outlined in the Prospectus Supplement [4]. Group 2: Regulatory and Legal Framework - The common shares will be issued under a prospectus supplement dated March 3, 2025, as part of an existing U.S. registration statement [5]. - The offering is being made solely through the Prospectus Supplement, which has been filed with the SEC [5]. - The press release clarifies that it does not constitute an offer to sell or solicit offers to buy securities in jurisdictions where such actions would be unlawful [6]. Group 3: Company Background - Zentek is an ISO 13485:2016 certified intellectual property technology company focused on developing and commercializing innovative products [7]. - The company’s patented technology platform, ZenGUARD™, enhances viral filtration efficiency for surgical masks and HVAC systems [8]. - Zentek holds a global exclusive license to an Aptamer-based platform technology developed by McMaster University, aimed at diagnostic and therapeutic markets [9].